Verve Therapeutics Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Cash & Equivalents	186.83	20.1	4.37
Short-Term Investments	115	-	-
Trading Asset Securities	99.61	38.45	-
Cash & Short-Term Investments	401.45	58.55	4.37
Cash Growth	585.62%	1238.94%	-
Accounts Receivable	3,001	0.65	-
Other Receivables	8.1	2.23	171.11
Receivables	3,009	2.88	171.11
Inventory	8,982	7,301	333.91
Prepaid Expenses	133.84	-	-
Other Current Assets	123.27	7.81	-
Total Current Assets	12,650	7,371	509.39
Property, Plant & Equipment	21.07	21.37	2.33
Long-Term Investments	-	5	-
Other Long-Term Assets	374.08	224	70
Total Assets	13,045	7,621	581.72
Accounts Payable	64.74	30.49	4.99
Accrued Expenses	1,230	1,215	20.97
Short-Term Debt	-	-	587
Current Portion of Long-Term Debt	-	249.71	-
Current Unearned Revenue	943.48	90.57	-
Other Current Liabilities	973.32	418.67	9.15
Total Current Liabilities	3,212	2,005	622.11
Long-Term Debt	4,665	2,064	-
Long-Term Unearned Revenue	1,704	-	-
Long-Term Deferred Tax Liabilities	227.36	153.97	-
Other Long-Term Liabilities	2,762	3,402	-
Total Liabilities	12,569	7,625	622.11
Common Stock	16.5	1.5	1.5
Retained Earnings	-307.19	-484.93	-41.89
Total Common Equity	-290.69	-483.43	-40.39
Shareholders' Equity	475.5	-4.56	-40.39
Total Liabilities & Equity	13,045	7,621	581.72
Total Debt	4,665	2,314	587
Net Cash (Debt)	-4,263	-2,255	-582.63
Net Cash Per Share	-3288.08	-15035.93	-3884.18
Filing Date Shares Outstanding	66.57	0.15	0.15
Total Common Shares Outstanding	1.65	0.15	0.15
Working Capital	9,438	5,366	-112.71
Book Value Per Share	-176.18	-3222.86	-269.25
Tangible Book Value	-290.69	-483.43	-40.39
Tangible Book Value Per Share	-176.18	-3222.86	-269.25
Buildings	7.13	3.75	2.74
Machinery	31.34	12.1	0.12
Construction In Progress	-	8.85	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.